GP-Leds

Leverage in the time of covid-19: Portfolio company debt

Secondaries funds are more exposed to individual companies than ever and will play a significant role in seeing them through the crisis.

Private equity is now a liquid asset class

Executives from Newbury Partners, Kirkland & Ellis, CPPIB, Lazard and HarbourVest Partners share their thoughts on the evolution of the secondaries market over the past decade.

Permira GP-led deal makes it across the line

Backers of the the $829m restructuring include Coller Capital, Neuberger Berman and Hellman & Friedman.

Morgan, Lewis & Bockius poaches team of secondaries lawyers

The team including partners Oliver Rochman and Rob Mailer comes from Morrison & Foerster.

Denominator effect impact to be less than post-GFC – Adams Street

Institutions hurt by ‘chronic corporate earnings disruption’, such as university endowments, could come under pressure to sell on the secondaries market.

The case for GP-leds versus preferred equity

The secondaries market offers various tools sponsors can use, regardless of the lack of visibility caused by the covid-19 crisis.

TR Capital closes in on Fund IV target

The Asian secondaries specialist is targeting $300m to invest out of offices in Hong Kong, Shanghai and Mumbai.

Manulife co-heads: The GP-led path to the secondaries market’s recovery

The secondaries market will play an important role in rejuvenating the economy, and its role will be more flexible, innovative and sophisticated than it has been in past crises.

Hedge fund side pockets and the covid-19 crisis

Dan Nolan of Duff & Phelps discusses how technology adopted from hedge funds can be used to contain the damage of the crisis.

The sellside evolved last year; expect even more surprises next year

Advisors are likely to widen their scope of deal type this year amid the pause in traditional LP sales and GP-led processes.